Topics
Low-grade gliomas | Treatment | Targeted therapy | Vorasidenib
Home > Publications > Topics > Low-grade gliomas > Treatment > Targeted terapy > Vorasidenib
*Silvani A, Franceschi E.
A
new era after a long wait: Vorasetinib, an inhibitor of mutant
IDH1 and IDH2 enzymes in patients with IDH-mutant glioma.
Tumori.
2024 Jan 2:3008916231217583. doi:
10.1177/03008916231217583. PMID:
38166539. Editorial. ˍ
Related
article:
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, et al.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Gatto L, Di Nunno V, Tosoni A,
Bartolini S, Ranieri L, Franceschi E.
Vorasidenib
in IDH1/2-mutant low-grade glioma: the grey zone of patient's
selection.
Front
Oncol. 2024 Jan
11;13:1339266. doi:
10.3389/fonc.2023.1339266. PMID:
38273856. Comment. ˍ
Related
article:
Mellinghoff
IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J,
Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y,
Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick
W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA,
Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY,
Cloughesy TF.
Vorasidenib
in IDH1- or IDH2-Mutant Low-Grade Glioma.
N
Engl J Med.
2023 Jun 4. doi:
10.1056/NEJMoa2304194. PMID:
37272516. Interventional study. ˍ
Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti
R.
IDH inhibition in gliomas: from
preclinical models to clinical trials.
Nat
Rev Neurol. 2024 May 17. doi:
10.1038/s41582-024-00967-7. PMID:
38760442. Review. ˍ